Movement Disorders (revue) - Checkpoint (Ncbi)

Index « Mesh.i » - entrée « Infusions, Intravenous »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Infusion Pumps, Implantable < Infusions, Intravenous < Infusions, Parenteral  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 24.
[0-20] [0 - 20][0 - 24][20-23][20-40]
Ident.Authors (with country if any)Title
000327 (2000) Werner Poewe [Autriche] ; G K WenningApomorphine: an underutilized therapy for Parkinson's disease.
000512 (2001) P. Del Dotto [Italie] ; N. Pavese ; G. Gambaccini ; S. Bernardini ; L V Metman ; T N Chase ; U. BonuccelliIntravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
000A80 (2003) William G. Ondo [États-Unis] ; Christine HunterFlumazenil, a GABA antagonist, may improve features of Parkinson's disease.
001168 (2005) Nicolas Simon [France] ; Joëlle Micallef ; Jean-Charles Reynier ; Monique Lesourd ; Tatiana Witjas ; André Alicherif ; Jean-Philippe Azulay ; Olivier BlinEnd-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study.
001429 (2006) Anna De Rosa [Italie] ; Pasquale Striano ; Fabrizio Barbieri ; Arturo De Falco ; Carlo Rinaldi ; Tecla Tucci ; Salvatore Striano ; Alessandro Filla ; Giuseppe De MicheleSuppression of myoclonus in SCA2 by piracetam.
001460 (1992) F. Stocchi [Italie] ; S. Ruggieri ; A. Carta ; J. Ryatt ; N. Quinn ; P. Jenner ; C D Marsden ; A. AgnoliIntravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease.
001717 (2006) Angela Deutschl Nder [Allemagne] ; Friedrich Asmus ; Elena Marelli ; Thomas Klopstock ; Thomas Gasser ; Kai BötzelExcellent response to apomorphine in Parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication.
001779 (2006) William G. Ondo [États-Unis] ; Yavuz S. SilayIntravenous flumazenil for Parkinson's disease: a single dose, double blind, placebo controlled, cross-over trial.
001B32 (2007) David Epstein [États-Unis] ; Marc DifazioOrofacial automatisms induced by acute withdrawal from high-dose midazolam mimicking nonconvulsive status epilepticus in a child.
001B33 (2007) Regina Katzenschlager [Royaume-Uni] ; Michael J. Jackson ; Sarah Rose ; Kim Stockwell ; Kayhan A. Tayarani-Binazir ; Mohammed Zubair ; Lance A. Smith ; Peter Jenner ; Andrew J. LeesAntiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
001D33 (1991) J P Stübgen [Afrique du Sud] ; B P LotzSegmental ballistic movement overflow myoclonus: a clinical, electromyographic, and pharmacologic evaluation.
001D83 (2007) Angelo Antonini [Italie] ; Ioannis U. Isaias ; Margherita Canesi ; Maurizio Zibetti ; Francesca Mancini ; Luigi Manfredi ; Marco Dal Fante ; Leonardo Lopiano ; Gianni PezzoliDuodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.
001E44 (2007) Carmine Vitale [Italie] ; Stefano Marconi ; Luigi Di Maio ; Giuseppe De Michele ; Katia Longo ; Vincenzo Bonavita ; Paolo BaroneShort-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial.
004534 (1989) D T Dexter [Royaume-Uni] ; P. Jenner ; C D MarsdenOxyferriscorbone elevates the total iron content of blood but not brain.
004608 (1988) S. Ruggieri [Italie] ; F. Stocchi ; A. Carta ; D. Bravi ; M. Bragoni ; L. Giorgi ; A. AgnoliComparison between L-dopa and lisuride intravenous infusions: a clinical study.
004730 (1995) R A Maricle [États-Unis] ; J G Nutt ; J H CarterMood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: preliminary findings.
004842 (1994) L V Metman [États-Unis] ; V H Sethy ; J R Roberts ; D. Bravi ; J I Hoff ; M M Mouradian ; T N ChaseMotor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease.
004982 (1993) M E Giuffra [États-Unis] ; V H Sethy ; T L Davis ; M M Mouradian ; T N ChaseMilacemide therapy for Parkinson's disease.
004A07 (1993) J G Nutt ; J H Carter ; W. Woodward ; J P Hammerstad ; S T GancherDoes tolerance develop to levodopa? Comparison of 2- and 21-H levodopa infusions.
004A66 (1995) J H Bower ; M D MuenterTemporary worsening of parkinsonism in a patient with Parkinson's disease after treatment with paclitaxel for a metastatic grade IV adenocarcinoma.
004C96 (1997) J G Nutt [États-Unis] ; J H Carter ; E S Lea ; W R WoodwardMotor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Mesh.i -k "Infusions, Intravenous" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Mesh.i  \
                -Sk "Infusions, Intravenous" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Ncbi
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Infusions, Intravenous
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024